Kohjin Bio Co., Ltd. (TYO:177A)
Japan · Delayed Price · Currency is JPY 1,016.00
+15.00 (1.50%)
Jun 3, 2026, 3:30 PM JST
Kohjin Bio Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 4,939 | 5,206 | 4,770 | 4,742 | 3,947 | |
Revenue Growth (YoY) | -5.13% | 9.14% | 0.59% | 20.14% | 25.81% |
Cost of Revenue | 3,082 | 2,841 | 2,889 | 2,288 | 1,907 |
Gross Profit | 1,857 | 2,365 | 1,881 | 2,454 | 2,040 |
Selling, General & Admin | 1,515 | 1,206 | 1,024 | 1,186 | 1,069 |
Research & Development | - | 168 | 240 | - | - |
Operating Expenses | 1,515 | 1,374 | 1,284 | 1,186 | 1,069 |
Operating Income | 342 | 991 | 597 | 1,268 | 971 |
Interest Expense | -38 | -30 | -22 | -32 | -38 |
Interest & Investment Income | 4 | 2 | - | - | - |
Earnings From Equity Investments | 33 | 98 | 71 | 10 | -29 |
Currency Exchange Gain (Loss) | -2 | - | 6 | -5 | 5 |
Other Non Operating Income (Expenses) | 2 | 3 | -18 | 2 | 9 |
EBT Excluding Unusual Items | 341 | 1,064 | 634 | 1,243 | 918 |
Gain (Loss) on Sale of Investments | -9 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | 1 | - | - | 1 |
Asset Writedown | -10 | - | - | - | - |
Other Unusual Items | 10 | -51 | - | - | 3 |
Pretax Income | 332 | 1,014 | 634 | 1,243 | 922 |
Income Tax Expense | 81 | 220 | 250 | 414 | 335 |
Net Income to Company | 251 | 794 | 384 | 829 | 587 |
Net Income | 251 | 794 | 384 | 829 | 587 |
Net Income to Common | 251 | 794 | 384 | 829 | 587 |
Net Income Growth | -68.39% | 106.77% | -53.68% | 41.23% | -15.77% |
Shares Outstanding (Basic) | 5 | 5 | 4 | 4 | 3 |
Shares Outstanding (Diluted) | 5 | 5 | 4 | 4 | 3 |
Shares Change (YoY) | 1.34% | 21.11% | - | 22.96% | - |
EPS (Basic) | 49.10 | 157.41 | 92.20 | 199.04 | 173.30 |
EPS (Diluted) | 49.10 | 157.41 | 92.20 | 199.04 | 173.30 |
EPS Growth | -68.81% | 70.74% | -53.68% | 14.85% | - |
Free Cash Flow | -272 | 53 | 261 | - | - |
Free Cash Flow Per Share | -53.21 | 10.51 | 62.66 | - | - |
Dividend Per Share | - | 24.000 | 14.000 | 19.000 | - |
Dividend Growth | - | 71.43% | -26.32% | - | - |
Gross Margin | 37.60% | 45.43% | 39.43% | 51.75% | 51.69% |
Operating Margin | 6.92% | 19.04% | 12.52% | 26.74% | 24.60% |
Profit Margin | 5.08% | 15.25% | 8.05% | 17.48% | 14.87% |
Free Cash Flow Margin | -5.51% | 1.02% | 5.47% | - | - |
EBITDA | 738 | 1,351 | 896 | - | - |
EBITDA Margin | 14.94% | 25.95% | 18.78% | - | - |
D&A For EBITDA | 396 | 360 | 299 | - | - |
EBIT | 342 | 991 | 597 | 1,268 | 971 |
EBIT Margin | 6.92% | 19.04% | 12.52% | 26.74% | 24.60% |
Effective Tax Rate | 24.40% | 21.70% | 39.43% | 33.31% | 36.33% |